Upperton Opens New Development and GMP Manufacturing Facility
Upperton Pharma Solutions was joined by Sarah Gilbert, Professor and co-creator of the Oxford/AstraZeneca COVID-19 vaccine for the official opening of its new development and GMP manufacturing facility in Nottingham, UK.
UK-based contract development and manufacturing organization (CDMO) Upperton Pharma Solutions recently celebrated the official opening of a new 50,000 square foot development and GMP manufacturing facility in Nottingham.
Nikki Whitfield, CEO of Upperton Pharma Solutions, commented, “This celebration marks another milestone in our incredible growth journey as a business. We are looking forward to officially opening our doors to customers and offering a single site solution for development and GMP manufacturing.”
The new facility contains ten GMP manufacturing suites, cutting-edge quality control laboratories, and formulation development capabilities equipped with a pilot plant. The facility enables Upperton to offer customers early formulation development to clinical trial supplies from Phase 1 to Phase 3 and niche scale commercial manufacturing all on one site.
“It was a pleasure to join Upperton for the grand opening of their new facility”, said Sarah Gilbert, co-creator of the Oxford/AstraZeneca COVID-19 vaccine. “During the pandemic we saw the importance of academia and industry working closely together to deliver life-saving vaccines and treatments. Upperton’s expansion into this new site is a great example of the crucial role UK-based pharmaceutical organisations have to play in addressing global health challenges. I look forward to collaborating with Upperton in the future.”
The official opening marks another milestone for Upperton following the announcement and ongoing build of a new sterile facility on the same site, for the manufacturing of aseptic and terminally sterilized small-volume liquids for parenteral, ocular, and pulmonary delivery due for completion at the end of 2024.
Company
Upperton Pharma SolutionsAlbert Einstein Centre, Nottingham Science Park
NG7 2TN Nottingham
UK
most read
Dow to Shut Down Three Upstream European Assets
Building on the April 2025 announcement, Dow will take actions across its three operating segments to support European profitability, resulting in the closure of sites in Germany and the UK.
Novo Nordisk to Cut 9,000 Jobs Globally in Major Restructuring
Novo Nordisk announced a global workforce reduction of approximately 9,000 positions to streamline operations and reinvest DKK 8 billion (€1 billion) in growth opportunities for diabetes and obesity treatments.
Ratcliffe: Chemical Industry in Europe at a Tipping Point
Ineos CEO Ineos calls on European politicians to save the chemical industry.
BASF Sells Majority Stake in Coatings Business
BASF sells a majority stake in its coatings business to the investor Carlyle.